\-\ Texto\\:\\ \ \(0\)\
\-\ \\.\\ \\ activity\\ within\\ the\\ kidneys\\ and\\ bladders\\ and\\ soft\\ tissues\\ are\ \(0\)\
\-\ unremarkable\\.2\\.\\ \\ there\\ is\\ increased\\ radiotracer\\ uptake\\ within\\ the\\ vertebral\\ body\\ and\\ left\ \(0\)\
\-\ posterior\\ rib\\ at\\ t5\\.\\ \\ there\\ is\\ also\\ increased\\ uptake\\ in\\ the\\ l4\\ vertebral\\ body\ \(0\)\
\-\ and\\ including\\ the\\ pedicles\\ at\\ this\\ level\\.\\ \\ there\\ is\\ increased\\ uptake\\ with\ \(0\)\
\-\ mild\\ expansion\\ of\\ the\\ sacrum\\.\\ \\ there\\ is\\ increased\\ uptake\\ and\\ expansion\\ of\\ the\ \(0\)\
\-\ left\\ iliac\\ crest\\ and\\ into\\ the\\ pubic\\ symphysis\\.\\ \\ the\\ remainder\\ of\\ the\\ skeleton\ \(0\)\
\-\ is\\ unremarkable\\.\ \(29\)\
\-\ paget\\ disease\\ of\\ bone\ \(0\)\
\-\ paget\\â\\€\\™s\\ disease\ \(0\)\
\-\ primary\\ bone\\ tumor\ \(12\)\
\-\ bony\\ metastasis\ \(0\)\
\-\ fibrous\\ dysplasia\ \(50\)\
\-\ 74\\ year\\ old\\ female\\ with\\ paget\\â\\€\\™s\\ disease\\.\ \(0\)\
\-\ paget\\â\\€\\™s\\ disease\\,\\ also\\ known\\ as\\ osteitis\\ deformans\\,\\ is\\ thought\\ to\\ be\\ caused\\ by\\ a\\ virus\\ and\\ may\\ affect\\ up\\ to\\ 3\\%\\ of\\ the\\ population\\ over\\ four\\ years\\ of\\ age\\.\\ \\ it\\ will\\ demonstrate\\ increased\\ bone\\ resorption\\ and\\ bone\\ formation\\.\\ \\ however\\,\\ the\\ newly\\ formed\\ bone\\ will\\ be\\ abnormally\\ soft\\.\\ \\ during\\ bone\\ formation\\,\\ the\\ patient\\ may\\ have\\ an\\ increase\\ in\\ their\\ alkaline\\ phosphatase\\.\\ \\ however\\,\\ their\\ calcium\\ and\\ phosphorus\\ levels\\ should\\ remain\\ normal\\.\\ \\ during\\ bone\\ resorption\\,\\ they\\ may\\ have\\ an\\ increased\\ hydroxyproline\\ level\\.\\ \\ paget\\â\\€\\™s\\ disease\\ typically\\ involves\\ the\\ spine\\,\\ pelvis\\,\\ and\\ proximal\\ long\\ bones\\.\\ \\ it\\ is\\ divided\\ into\\ three\\ phases\\:\\ osteolytic\\ phase\\,\\ osteoblastic\\ and\\ mixed\\ phases\\.\\ \\ the\\ initial\\ osteolytic\\ or\\ the\\ active\\ phase\\ is\\ characterized\\ by\\ aggressive\\ bone\\ resorption\\ and\\ lytic\\ lesions\\.\\ \\ the\\ osteoblastic\\ phase\\ or\\ inactive\\ phase\\ is\\ distinguished\\ by\\ abnormal\\ bone\\ production\\ such\\ as\\ cortical\\ thickening\\ and\\ bone\\ widening\\.\\ \\ overall\\ bone\\ density\\ is\\ also\\ increased\\ at\\ this\\ phase\\.\\ the\\ mixed\\ phase\\ demonstrates\\ bone\\ resorption\\ and\\ formation\\ and\\ bowing\\ of\\ bones\\ is\\ prominent\\ at\\ this\\ time\\.\\ bone\\ scans\\ are\\ performed\\ with\\ tc99m\\ hdp\\ which\\ will\\ show\\ striking\\ uptake\\ during\\ the\\ osteoblastic\\ phase\\ and\\ will\\ typically\\ show\\ enlargement\\ of\\ the\\ bone\\ along\\ with\\ characteristic\\ paget\\â\\€\\™s\\ disease\\ bone\\ deformities\\ and\\ expansion\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ bone\\:\\ 0\\.09536383299969475\ \(0\)\
\-\ paget\\:\\ 0\\.08511343077953494\ \(0\)\
\-\ phase\\:\\ 0\\.0842457938580488\ \(0\)\
\-\ resorption\\:\\ 0\\.06524817477820388\ \(0\)\
\-\ uptake\\:\\ 0\\.050823105160092995\ \(0\)\
\-\ osteoblastic\\:\\ 0\\.04925132257896372\ \(0\)\
\-\ increased\\:\\ 0\\.04381255530717841\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.03823393322822539\ \(0\)\
\-\ expansion\\:\\ 0\\.03781749914351862\ \(0\)\
\-\ s\\:\\ 0\\.036688138729260286\ \(0\)\
\-\ osteolytic\\:\\ 0\\.03455686219307231\ \(0\)\
\-\ phases\\:\\ 0\\.033512829934720344\ \(0\)\
\-\ will\\:\\ 0\\.032017736747055596\ \(0\)\
\-\ formation\\:\\ 0\\.03168189874196374\ \(0\)\
\-\ bladders\\:\\ 0\\.026393767736426644\ \(0\)\
\-\ unremarkable\\.2\\:\\ 0\\.026393767736426644\ \(0\)\
\-\ disease\\:\\ 0\\.02509109355477313\ \(0\)\
\-\ during\\:\\ 0\\.023488107035243785\ \(0\)\
\-\ hydroxyproline\\:\\ 0\\.023104509387120924\ \(0\)\
\-\ mixed\\:\\ 0\\.022472595155326538\ \(0\)\
\-\ their\\:\\ 0\\.02239727310618366\ \(0\)\
\-\ deformans\\:\\ 0\\.02224318581690601\ \(0\)\
\-\ bones\\:\\ 0\\.02159300761152741\ \(0\)\
\-\ vertebral\\:\\ 0\\.02025027796654047\ \(0\)\
\-\ inactive\\:\\ 0\\.020167894857145697\ \(0\)\
\-\ hdp\\:\\ 0\\.020167894857145697\ \(0\)\
\-\ pedicles\\:\\ 0\\.01949980039213309\ \(0\)\
\-\ phosphorus\\:\\ 0\\.019214440572359666\ \(0\)\
\-\ t5\\:\\ 0\\.018714278642230422\ \(0\)\
\-\ osteitis\\:\\ 0\\.018714278642230422\ \(0\)\
\-\ is\\:\\ 0\\.018518558569556833\ \(0\)\
\-\ crest\\:\\ 0\\.01828583300258769\ \(0\)\
\-\ tc99m\\:\\ 0\\.01828583300258769\ \(0\)\
\-\ typically\\:\\ 0\\.018062429757520794\ \(0\)\
\-\ symphysis\\:\\ 0\\.0179110930536236\ \(0\)\
\-\ striking\\:\\ 0\\.017424509432372778\ \(0\)\
\-\ distinguished\\:\\ 0\\.017278431096536154\ \(0\)\
\-\ newly\\:\\ 0\\.017006060503105835\ \(0\)\
\-\ may\\:\\ 0\\.01683528475058195\ \(0\)\
\-\ virus\\:\\ 0\\.016756414967360172\ \(0\)\
\-\ phosphatase\\:\\ 0\\.016756414967360172\ \(0\)\
\-\ body\\:\\ 0\\.01661834558496458\ \(0\)\
\-\ pubic\\:\\ 0\\.01641710752632124\ \(0\)\
\-\ bowing\\:\\ 0\\.01641710752632124\ \(0\)\
\-\ alkaline\\:\\ 0\\.01631204369455097\ \(0\)\
\-\ sacrum\\:\\ 0\\.016112368920602853\ \(0\)\
\-\ divided\\:\\ 0\\.016112368920602853\ \(0\)\
\-\ formed\\:\\ 0\\.015835802093863285\ \(0\)\
\-\ show\\:\\ 0\\.01570752056581812\ \(0\)\
\-\ skeleton\\:\\ 0\\.015664669118294578\ \(0\)\
\-\ production\\:\\ 0\\.01550279121029974\ \(0\)\
\-\ there\\:\\ 0\\.015230126424730404\ \(0\)\
\-\ l4\\:\\ 0\\.015132689545727353\ \(0\)\
\-\ also\\:\\ 0\\.015131313715600161\ \(0\)\
\-\ level\\:\\ 0\\.014747838488903785\ \(0\)\
\-\ affect\\:\\ 0\\.0147416111552571\ \(0\)\
\-\ 74\\:\\ 0\\.014621834704317882\ \(0\)\
\-\ deformities\\:\\ 0\\.014450701728749174\ \(0\)\
\-\ remain\\:\\ 0\\.014341816566560925\ \(0\)\
\-\ however\\:\\ 0\\.01424771290776689\ \(0\)\
\-\ abnormally\\:\\ 0\\.014085762155069423\ \(0\)\
\-\ at\\:\\ 0\\.013865426980019557\ \(0\)\
\-\ population\\:\\ 0\\.013349729333164391\ \(0\)\
\-\ widening\\:\\ 0\\.012888200351645656\ \(0\)\
\-\ rib\\:\\ 0\\.012791088747594296\ \(0\)\
\-\ by\\:\\ 0\\.012780277574055761\ \(0\)\
\-\ iliac\\:\\ 0\\.01275940578552682\ \(0\)\
\-\ characterized\\:\\ 0\\.012728054588319349\ \(0\)\
\-\ overall\\:\\ 0\\.012728054588319349\ \(0\)\
\-\ calcium\\:\\ 0\\.012517333639930727\ \(0\)\
\-\ aggressive\\:\\ 0\\.012517333639930727\ \(0\)\
\-\ soft\\:\\ 0\\.0124606393053506\ \(0\)\
\-\ into\\:\\ 0\\.012175606993770701\ \(0\)\
\-\ remainder\\:\\ 0\\.012059960123306745\ \(0\)\
\-\ radiotracer\\:\\ 0\\.01193773858282694\ \(0\)\
\-\ scans\\:\\ 0\\.011913881787470122\ \(0\)\
\-\ involves\\:\\ 0\\.011890213585353016\ \(0\)\
\-\ kidneys\\:\\ 0\\.011774600303533316\ \(0\)\
\-\ thought\\:\\ 0\\.011774600303533316\ \(0\)\
\-\ it\\:\\ 0\\.011502086134928244\ \(0\)\
\-\ lytic\\:\\ 0\\.011452352805951383\ \(0\)\
\-\ four\\:\\ 0\\.011106505838520712\ \(0\)\
\-\ have\\:\\ 0\\.011080467535120311\ \(0\)\
\-\ characteristic\\:\\ 0\\.010829405367367284\ \(0\)\
\-\ caused\\:\\ 0\\.010731765889556622\ \(0\)\
\-\ increase\\:\\ 0\\.010731765889556622\ \(0\)\
\-\ levels\\:\\ 0\\.010560632913987913\ \(0\)\
\-\ tissues\\:\\ 0\\.010500750678339202\ \(0\)\
\-\ prominent\\:\\ 0\\.010500750678339202\ \(0\)\
\-\ fibrous\\:\\ 0\\.010341994785200818\ \(0\)\
\-\ bony\\:\\ 0\\.010231603959427382\ \(0\)\
\-\ enlargement\\:\\ 0\\.010151402414626035\ \(0\)\
\-\ dysplasia\\:\\ 0\\.010099103932469176\ \(0\)\
\-\ active\\:\\ 0\\.009768140236661319\ \(0\)\
\-\ within\\:\\ 0\\.009761265918479532\ \(0\)\
\-\ activity\\:\\ 0\\.009598942002339936\ \(0\)\
\-\ metastasis\\:\\ 0\\.009577087803293194\ \(0\)\
\-\ cortical\\:\\ 0\\.009326571408909617\ \(0\)\
\-\ pelvis\\:\\ 0\\.00929668085805877\ \(0\)\
\-\ including\\:\\ 0\\.009237780362254264\ \(0\)\
\-\ they\\:\\ 0\\.0092184015763093\ \(0\)\
\-\ and\\:\\ 0\\.009162135022298543\ \(0\)\
\-\ long\\:\\ 0\\.008821022487523126\ \(0\)\
\-\ thickening\\:\\ 0\\.008672528651776503\ \(0\)\
\-\ this\\:\\ 0\\.00863296898186347\ \(0\)\
\-\ three\\:\\ 0\\.008624623438164402\ \(0\)\
\-\ initial\\:\\ 0\\.008477790848141641\ \(0\)\
\-\ unremarkable\\:\\ 0\\.008470258738569044\ \(0\)\
\-\ along\\:\\ 0\\.008455251128318911\ \(0\)\
\-\ spine\\:\\ 0\\.008425459718578887\ \(0\)\
\-\ density\\:\\ 0\\.008418057954670537\ \(0\)\
\-\ should\\:\\ 0\\.008156312999667067\ \(0\)\
\-\ known\\:\\ 0\\.00809596133073\ \(0\)\
\-\ such\\:\\ 0\\.00799800236479297\ \(0\)\
\-\ be\\:\\ 0\\.007890758822418738\ \(0\)\
\-\ the\\:\\ 0\\.007864480267571528\ \(0\)\
\-\ age\\:\\ 0\\.007787156663306307\ \(0\)\
\-\ as\\:\\ 0\\.0077399850652342984\ \(0\)\
\-\ proximal\\:\\ 0\\.007681267011098848\ \(0\)\
\-\ primary\\:\\ 0\\.007578994799088912\ \(0\)\
\-\ years\\:\\ 0\\.007512704003049349\ \(0\)\
\-\ abnormal\\:\\ 0\\.007296683354236262\ \(0\)\
\-\ \\,\\:\\ 0\\.007294582603759241\ \(0\)\
\-\ time\\:\\ 0\\.007226350979758421\ \(0\)\
\-\ performed\\:\\ 0\\.007133468057566824\ \(0\)\
\-\ an\\:\\ 0\\.0070758375106870055\ \(0\)\
\-\ are\\:\\ 0\\.006975292649877855\ \(0\)\
\-\ up\\:\\ 0\\.006879781889383902\ \(0\)\
\-\ lesions\\:\\ 0\\.006848983551927987\ \(0\)\
\-\ mild\\:\\ 0\\.006737285790212985\ \(0\)\
\-\ over\\:\\ 0\\.00651389997047893\ \(0\)\
\-\ or\\:\\ 0\\.005997142209363518\ \(0\)\
\-\ 3\\:\\ 0\\.005990944690738143\ \(0\)\
\-\ \\%\\:\\ 0\\.005968027045946131\ \(0\)\
\-\ tumor\\:\\ 0\\.0059647673700922495\ \(0\)\
\-\ posterior\\:\\ 0\\.005897121403300744\ \(0\)\
\-\ demonstrate\\:\\ 0\\.00588758126147617\ \(0\)\
\-\ left\\:\\ 0\\.005725181253131226\ \(0\)\
\-\ demonstrates\\:\\ 0\\.005588686232494569\ \(0\)\
\-\ female\\:\\ 0\\.005259761291759982\ \(0\)\
\-\ which\\:\\ 0\\.004775881997732182\ \(0\)\
\-\ normal\\:\\ 0\\.004010815732332638\ \(0\)\
\-\ \\:\\:\\ 0\\.0033840563353013924\ \(0\)\
\-\ year\\:\\ 0\\.002862590626565613\ \(0\)\
\-\ of\\:\\ 0\\.002790510198754214\ \(0\)\
\-\ old\\:\\ 0\\.0026195646612642356\ \(0\)\
\-\ patient\\:\\ 0\\.0025646464997496647\ \(0\)\
\-\ to\\:\\ 0\\.002557294062532852\ \(0\)\
\-\ in\\:\\ 0\\.0025233367074266764\ \(0\)\
\-\ \\.\\:\\ 0\\.002232006760611592\ \(0\)\
\-\ with\\:\\ 0\\.001401247617842991\ \(0\)\
\-\ a\\:\\ 0\\.0011874245563431177\ \(0\)\
